Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Obermayr

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Oncotarget|January 2, 2018
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortiumEva Obermayr, Natalia Bednarz-Knoll, Beatrice Orsetti, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
International Journal of Cancer|April 27, 2024
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortiumEva Obermayr, Thomas Mohr, Eva Schuster, et al.
International Journal of Cancer|May 6, 2024
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortiumGesa Fromhage, Eva Obermayr, Natalia Bednarz-Knoll, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Cancer Letters|March 26, 2026
Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancerAhmed El-Gazzar, Bertram Aschenbrenner, Agnes Forsthuber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Oncotarget|January 2, 2018
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortiumEva Obermayr, Natalia Bednarz-Knoll, Beatrice Orsetti, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
International Journal of Cancer|April 27, 2024
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortiumEva Obermayr, Thomas Mohr, Eva Schuster, et al.
International Journal of Cancer|May 6, 2024
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortiumGesa Fromhage, Eva Obermayr, Natalia Bednarz-Knoll, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2013
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortiumDietmar Pils, Anna Bachmayr-Heyda, Katharina Auer, et al.
Oncogene|July 4, 2023
Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortiumNicole Heinzl, Elisabeth Maritschnegg, Katarzyna Koziel, et al.
Cancer Letters|March 26, 2026
Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancerAhmed El-Gazzar, Bertram Aschenbrenner, Agnes Forsthuber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
Pageof 4